Subsequently, overall survival (OS) analysis indeed confirmed that cases exhibiting high PAN3-AS1 levels had poor survival rates when they received PD1 and CTLA4 antibody treatment in melanoma (Fig. 6A). This evidence concerns the gene PAN3 and melanoma.